6-(4-arylalkylpiperazin-1-yl) benzodioxane and 6-(arylalkylpiperazin-1-yl) chromane derivatives: dopamine receptor subtype specific ligands

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of the formula:

• or the pharmaceutically acceptable acid addition salts thereof wherein:
• R1, R2, R3, R4 and R5 are the same or different and represent hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C4 alkylthio, hydroxy, amino, mono- or di(C1-C6)alkylamino, cyano, nitro, trifluoromethyl or trifluoromethoxy;
• and
• R6, R7, R8 and R9 are the same or different and are hydrogen or C1-C5 alkyl.

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of the formula:

• or the pharmaceutically acceptable acid addition salts thereof wherein:
• R1, R2, R3, R4 and R5 are the same or different and represent hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C4 alkylthio, hydroxy, amino, mono- or di(C1-C6)alkylamino, cyano, nitro, trifluoromethyl or trifluoromethoxy;
• and
• R6, R7, R8 and R9 are the same or different and are hydrogen or C1-C6 alkyl.

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of the formula:

• our the pharmaceutically acceptable acid addition salts thereof wherein:
• R1, R2, R3, R4 and R5 are the same or different and represent hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C4 alkylthio, hydroxy, amino, mono- or di(C1-C6)alkylamino, cyano, nitro, trifluoromethyl or trifluoromethoxy;
• and
• R6, R7, R8 and R9 are the same or different and are hydrogen or C1-C6 alkyl.